Research Article
Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances
Table 1
Baseline demographic and clinical characteristics.
| Patient | Age/gender | Histologic subtype | Localization | Primary/recurrent | TNM | Treatment (months) | Margins | Adjuvant therapy (months) | Clinical response | Follow-up(months) | Final outcome |
| 1 | 42 F | Infiltrative | MC | Recurrent | T4a | Exenteration | Positive | RT | Progression | 44 | Exitus | 2 | 78 M | Infiltrative | MC | Primary | T4a | Conservative surgery | Negative | | CR | 60 | NED | 3 | 60 F | Infiltrative | MC | Primary | T4a | Conservative surgery | Negative | | CR | 64 | NED | 4 | 75 M | Infiltrative | LC + UE | Recurrent | T4b | Exenteration | Negative | | CR | 76 | NED | 5 | 84 F | Infiltrative | MC + LE | Recurrent | T4b | Exenteration | Negative | | CR | 72 | Exitus | 6 | 85 F | Infiltrative | LE | Recurrent | T4b | Exenteration | Negative | | CR | 70 | Exitus | 7 | 82 M | Infiltrative | LE | Recurrent | T4a | Exenteration | Negative | | CR | 60 | Exitus | 8 | 91 F | Basosquamous | MC + UE + LE + LC | Recurrent | T4a | Exenteration | Negative | | CR | 36 | Exitus | 9 | 77 F | Infiltrative | MC | Recurrent | T4a | Vismodegib (12) | | | CR | 48 | NED | 10 | 84 M | Infiltrative | LE | Recurrent | T4a | Conservative surgery | Negative | | CR | 41 | Exitus | 11 | 70 M | Infiltrative | MC | Recurrent | T4b | Exenteration | Negative | | CR | 60 | NED | 12 | 64 M | Infiltrative | MC | Primary | T4a | Conservative surgery | Negative | | CR | 72 | NED | 13 | 72 M | Infiltrative | MC | Primary | T4a | Conservative surgery | Negative | | CR | 59 | NED | 14 | 82 F | Infiltrative | MC | Recurrent | T4a | Exenteration | Negative | | CR | 44 | NED | 15 | 81 F | Infiltrative | MC | Recurrent | T4b | Exenteration | Positive | Vismodegib (8) | CR | 42 | NED | 16 | 45 M | Infiltrative | MC | Recurrent | T4a | Conservative surgery | Positive | Vismodegib (58) | CR | 62 | NED | 17 | 57 M | Infiltrative | MC | Recurrent | T4a | Conservative surgery | Negative | | CR | 60 | NED | 18 | 78 F | Infiltrative | MC | Recurrent | T4a | Conservative surgery | Negative | | CR | 62 | NED | 19 | 52 M | Infiltrative | LC + LE | Primary | T4a | Conservative surgery | Negative | | CR | 54 | NED | 20 | 54 M | Infiltrative | LC + LE | Primary | T4a | Conservative surgery | Negative | | CR | 62 | NED | 21 | 79 F | Infiltrative | MC | Recurrent | T4a | Conservative surgery | Positive | Vismodegib (10) | CR | 44 | NED | 22 | 67 M | Infiltrative | MC | Recurrent | T4a | Vismodegib (3) | | | | 12 | Exitus | 23 | 95 F | Infiltrative | MC | Primary | T4a | Vismodegib (1) | | | | 8 | Exitus | 24 | 72 M | Micronodular | MC | Recurrent | T4a | Conservative surgery | Positive | Vismodegib (10) | CR | 36 | NED |
|
|
F: female, M: male, TNM: staging tumor node metastasis [ 19], MC: medial canthus, LC: lateral canthus, UE: upper eyelid, LE: lower eyelid, not due to cancer, due to lung cancer, RT: radiotherapy, CR: complete remission, NED: no evidence of disease. |